Consistent with this, it was recently demonstrated in NSCLC that patients who had high tumour mutational burdens (TMB) but also loss of heterozygosity at the HLA locus (LOHHLA) had inferior response rates to anti-PD-(L)1 therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.